These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2017196)

  • 1. A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.
    Tan LU; Fahim RE; Jackson G; Phillips K; Wah P; Alkema D; Zobrist G; Herbert A; Boux L; Chong P
    Mol Immunol; 1991 Mar; 28(3):251-5. PubMed ID: 2017196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simple, efficient purification of filamentous hemagglutinin and pertussis toxin from Bordetella pertussis by hydrophobic and affinity interaction.
    Skelton SK; Wong KH
    J Clin Microbiol; 1990 May; 28(5):1062-5. PubMed ID: 2351723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
    Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
    Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The purification and characterization of an acellular pertussis vaccine.
    Chazono M; Yoshida I; Konobe T; Fukai K
    J Biol Stand; 1988 Apr; 16(2):83-9. PubMed ID: 2897370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
    Olander RM; Muotiala A; Karvonen M; Kuronen T; Runeberg-Nyman K
    Microb Pathog; 1990 Jan; 8(1):37-45. PubMed ID: 2159104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of filamentous hemagglutinin from Bordetella pertussis and assay for serum antibodies to filamentous hemagglutinin and pertussis toxin for clinical and public health laboratories.
    Wong KH; Skelton SK
    J Clin Microbiol; 1989 Dec; 27(12):2805-10. PubMed ID: 2556434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure.
    Christodoulides M; Sidey FM; Parton R; Stewart-Tull DE
    Vaccine; 1987 Sep; 5(3):199-207. PubMed ID: 2890244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
    Sato Y; Sato H
    Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
    Kimura M; Kuno-Sakai H; Kamiya H; Ueda K; Isomura S; Koike M; Kato T; Ozaki T; Hirose M; Egami T
    Acta Paediatr Jpn; 1995 Oct; 37(5):562-74. PubMed ID: 8533580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
    Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
    Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering bacterial toxin for the development of new vaccine against pertussis.
    Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
    Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
    Novotny P; Chubb AP; Cownley K; Charles IG
    Dev Biol Stand; 1991; 73():243-9. PubMed ID: 1778316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model.
    Watanabe M; Komatsu E; Abe K; Iyama S; Sato T; Nagai M
    Vaccine; 2002 Jan; 20(9-10):1429-34. PubMed ID: 11818163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective activities in mice of monoclonal antibodies against pertussis toxin.
    Sato H; Sato Y
    Infect Immun; 1990 Oct; 58(10):3369-74. PubMed ID: 1698179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
    Thomas MG; Ashworth LA; Miller E; Lambert HP
    J Infect Dis; 1989 Nov; 160(5):838-45. PubMed ID: 2572651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
    Podda A; Nencioni L; Marsili I; Peppoloni S; Volpini G; Donati D; Di Tommaso A; De Magistris MT; Rappuoli R
    Vaccine; 1991 Oct; 9(10):741-5. PubMed ID: 1759492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
    Sato H; Sato Y
    Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.